Sean Jeong

Sean (Seungwon) Jeong has a diverse work experience spanning multiple industries and roles. Sean (Seungwon) currently serves as the President and CEO of HanAll Biopharma since March 2021, and previously held the position of President from June 2020 to March 2021. Sean (Seungwon) is also a Board Member at Daewoong Investment starting from March 2023. In addition, they have held positions as a Board Member at NurrOn Pharmaceuticals from November 2021 to November 2023, and as a Board Member at ImmunoMet Therapeutics, Inc. from February 2021 to December 2022.

Prior to their current positions, Jeong worked at UCB as the Head of Bone Japan/China from July 2018 to May 2020, and as the Head of Bone Japan from March 2017 to July 2018. Sean (Seungwon) also has experience at Novartis, where they held various roles including New Products Director - Neuroscience, Regional Brand Director for China/Japan - Neuroscience, Head of Marketing, Neuroscience Business Franchise - Japan, Global Program Strategic Marketing Director - Respiratory, Head of Neuroscience Business Unit, and Senior Insights Manager.

Jeong began their career as a Summer Associate at Merck & Co. in 2004, and as a Medical Advisor at Organon in 2002. Sean (Seungwon) also worked as an Associate Consultant at Bain & Company from 2000 to 2002. Prior to their corporate career, Jeong served as a Physician/Manager at Jeju Combat Police from May 1998 to April 2000.

Sean (Seungwon) Jeong obtained an MBA degree in Management from the MIT Sloan School of Management, where they studied from 2003 to 2005. Prior to that, they earned an MD degree in Medicine from Yonsei University, attending from 1991 to 1997. In addition to their academic qualifications, they hold a Japanese-Language Proficiency Test - N2 certification from Japan Educational Exchanges and Services, obtained in 2018. Sean (Seungwon) is also certified by the Educational Commission for Foreign Medical Graduates (ECFMG).